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DeOBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following
high-intensity statin therapy.
BACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular
disease.
METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvas-
tatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosu-
vastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ signiﬁcantly in change from
baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or
clinical outcomes.
RESULTS Compared with men (n ¼ 765), women (n ¼ 274) were older (p < 0.001) and more likely to have hypertension
(p < 0.001), diabetes (p ¼ 0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p ¼ 0.01), high-density
lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p ¼ 0.004) levels. At follow-up, women had higher
high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p ¼ 0.46) levels compared with
men. Compared with men, women had lower baseline PAV (34.0  8.0% vs. 37.2  8.2%, p < 0.001) and TAV (122.4 
55 mm3 vs. 151.9  63 mm3, p < 0.001), yet demonstrated greater PAV regression (–1.52  0.18% vs. –1.07  0.10%,
p ¼ 0.03) and TAV regression (–8.27  0.9 mm3 vs. –6.59  0.50 mm3, p ¼ 0.11) following treatment. Greater PAV
regression in women versus men occurred with rosuvastatin (p ¼ 0.004), those with diabetes (p ¼ 0.01), stable coronary
disease (p ¼ 0.01), higher baseline LDL-C (p ¼ 0.02), and higher CRP (p ¼ 0.04) levels. On multivariable analysis, female
sex was independently associated with PAV regression (p¼ 0.01), and a sex-treatment interaction was found (p¼ 0.036).
For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (–1.81  0.22% vs.
–1.12 0.13%, p ¼ 0.007) and TAV regression (–10.1 1.1 mm3 vs. –7.16  0.65 mm3, p ¼ 0.023) than men, whereas PAV
and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.
CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when
empirically prescribed guideline-driven potent statin therapy. This beneﬁt appears in the setting of lower on-treatment
LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img
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CRP = C-reactive protein
EEM = external elastic
membrane
IVUS = intravascular
ultrasound
HDL-C = high-density
lipoprotein cholesterol
LDL-C = low-density
lipoprotein cholesterol
PAV = percent atheroma
volume
TAV = total atheroma volume
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1014O ver the course of the last 2 decades,randomized clinical trials andmeta-analyses demonstrated the
unequivocal beneﬁts of statin-mediated
cholesterol lowering in the prevention of car-
diovascular events (1–3). Recent guidelines
have shifted emphasis away from targeting
speciﬁc low-density lipoprotein cholesterol
(LDL-C) goals, and now endorse the broad
use of high-intensity statins in all individuals
with atherosclerotic cardiovascular disease
(4). Despite the enrollment of both sexes in
clinical trials employing statins, the antia-
therosclerotic effects of high-intensity statinsin women compared with men remains relatively un-
explored. Moreover, some continue to question the
merits of statins in women (5,6), particularly in the pri-
mary preventative setting. Much of this controversy
stems from the consistent under-representation of
women in randomized clinical trials (7). AlthoughSEE PAGE 1023cardiovascular events are a leading cause of death in
women, debate regarding the beneﬁts of statins, in
addition to other therapeutic strategies, may con-
tribute to a sex disparity in the implementation of
evidence-based strategies for the treatment of cardio-
vascular disease (8,9).
Intravascular ultrasound (IVUS) enabled charac-
terization of factors promoting coronary atheromaN (Study of Coronary Atheroma by Intravascular Ultrasound: Ef
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received February 12, 2014; revised manuscript received Marchprogression and for quantifying the ability of
antiatherosclerotic strategies to slow disease pro-
gression. Although high doses of potent statins
can regress coronary atheroma (10,11), and lower
clinical event rates (12,13), there are currently no
reports of differential sex-related effects of high-
intensity statin therapy. The SATURN (Study of
Coronary Atheroma by Intravascular Ultrasound:
Effect of Rosuvastatin Versus Atorvastatin) study
was a randomized controlled trial employing
serial IVUS to evaluate the antiatherosclerotic efﬁ-
cacy of rosuvastatin and atorvastatin, each pre-
scribed at their highest approved doses during a
24-month study period (11). By performing a post-
hoc subgroup analysis of the SATURN study, we
tested the hypothesis that there would be sex-
speciﬁc variations in the effects of maximally
intensive statin therapy on coronary atheroma
progression.
METHODS
PATIENT SELECTION. The design of the SATURN
study has been previously described (14). Brieﬂy,
patients with angiographically demonstrable coro-
nary disease and LDL-C <116 mg/dl following a 2-
week treatment period with atorvastatin 40 mg or
rosuvastatin 20 mg daily, were re-randomized and
treated for 24 months with atorvastatin 80 mg or
rosuvastatin 40 mg daily. Subjects underwent IVUSfect of Rosuvastatin Versus Atorvastatin) study was
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TABLE 1 Demographics, Baseline Characteristics, and Concomitant Medications
Total
(N ¼ 1,039)
Women
(n ¼ 274)
Men
(n ¼ 765) p Value
Age, yrs 57.6  8.6 59.2  8.5 57.1  8.5 <0.001
Body mass index, kg/m2 29.0  5.2 29.4  5.9 28.9  5.0 0.66
Previous MI 254 (24.4) 50 (18.2) 204 (26.7) 0.005
Hypertension 731 (70.4) 220 (80.3) 511 (66.8) <0.001
Diabetes mellitus 159 (15.3) 58 (21.2) 101 (13.2) 0.002
Current smoker 336 (32.3) 89 (32.5) 247 (32.3) 0.95
ACS at presentation 361 (34.7) 82 (29.9) 279 (36.5) 0.051
Rosuvastatin 520 (50.0) 141 (51.5) 379 (49.5) 0.59
Aspirin 638 (61.4) 153 (55.8) 485 (63.4) 0.03
Beta-blockers 632 (60.8) 152 (55.5) 480 (62.7) 0.03
ACE inhibitors 457 (44.0) 111 (40.5) 346 (45.2) 0.18
Angiotensin receptor blocker 170 (16.4) 54 (19.7) 116 (15.2) 0.08
Nitrates 859 (82.7) 215 (78.5) 644 (84.2) 0.03
Values are mean  SD, median (interquartile range), or n (%). All medications listed are concomitant.
ACE ¼ angiotensin-converting enzyme inhibitor; ACS ¼ acute coronary syndrome; MI ¼ myocardial infarction.
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1015imaging of a coronary artery at baseline and after 104
weeks of treatment.
ACQUISITION AND ANALYSIS OF INTRAVASCULAR
CORONARY IMAGING. The presence of at least a
single lumen stenosis of >20% angiographic diam-
eter stenosis severity in an epicardial coronary artery
at the time of a clinically indicated coronary angio-
gram was necessary for enrollment eligibility. IVUS
was performed at baseline in a single, native coro-
nary artery with no lumen stenosis of $50% angio-
graphic diameter stenosis severity, which had not
undergone revascularization and was not considered
to be the culprit vessel of a prior myocardial infarc-
tion. Images were screened by the Atherosclerosis
Imaging Core Laboratory of the Cleveland Clinic
Coordinating Center for Clinical Research for quality,
and patients whose baseline imaging met these
requirements were eligible for randomization.
Following 104 weeks of treatment, patients under-
went a second IVUS of the same artery. Anatomi-
cally-matched arterial segments were selected for
analysis on the basis of proximal and distal land-
marks. Cross-sectional images spaced 1 mm apart
were selected for analysis, with lumen and external
elastic membrane (EEM) leading edges deﬁned by
manual planimetry. Plaque area was determined as
the area between these leading edges. Percent
atheroma volume (PAV) (a measure of plaque burden
representing the percent of the EEM volume occu-
pied by atheroma), the primary efﬁcacy endpoint in
the SATURN study, was calculated as previously
described (15). Total atheroma volume (TAV) (simply
the gross volume of atheroma normalized for length),
the secondary efﬁcacy endpoint in the SATURN
study, was also calculated as previously described
(15). Change in plaque burden was calculated as the
PAV (or TAV) at 104 weeks minus the corresponding
PAV (or TAV) at baseline. Plaque regression was
deﬁned as any decrease in PAV (or TAV) from base-
line. The post-hoc analyses presented here pooled
results from both treatment groups, as in the
SATURN study, rosuvastatin and atorvastatin did not
differ in the primary efﬁcacy endpoint of the change
in PAV from baseline.
STATISTICAL ANALYSES. Continuous variables were
reported as mean  SD if normally distributed and as
median (interquartile range) if not normally distrib-
uted. Demographics, baseline clinical characteristics,
follow-up medications, laboratory biochemical
data, and baseline IVUS parameters were compared
between men and women. Two-sample t tests
were used for normally distributed continuous vari-
ables, Wilcoxon rank sum tests for non-normallydistributed continuous variables, and chi-square
tests for categorical variables. Serial changes in
IVUS measurements were analyzed by an analysis of
variance adjusting for their baseline counterparts
and were reported as least-squares mean  SE. Given
the apparent sex-related differences of change in
PAV, subgroup analyses were performed to analyze
effects of various clinical characteristic subgroups as
well as their interaction effects with sex upon change
in PAV. Because the treatment showed a signiﬁcant
interaction effect with sex, a 2-way analysis of vari-
ance was performed to assess for a sex by treatment
effect upon change in PAV adjusting for covariates.
To identify covariates, a bootstrap resampling (1,000
iterations and a p value criterion of 0.05 for reten-
tion) was undertaken for demographic and clinical
characteristics. Those variables having at least a 40%
probability of retention were entered into a second
linear regression model with the stepwise model se-
lection procedure. The signiﬁcance level to enter and
keep a variable was set at 0.05. The selected cova-
riates formed the covariate set for the ﬁnal multivar-
iable model. The same multivariable model selection
procedure was repeated for changes in TAV.
Furthermore, the relationships between change in
PAV and average (on-treatment) LDL-C and between
change in TAV and average (on-treatment) LDL-C,
were compared between sexes using local regres-
sion via the LOESS (Locally Weighted Scatter plot
Smoothing) method. A 2-sided p value of 0.05 was
considered statistically signiﬁcant. All analyses were
performed using SAS software version 9.2 (SAS
Institute, Cary, North Carolina).
TABLE 2 Laboratory
Baseline
LDL-C
HDL-C
Non–HDL-C
Triglycerides 1
ApoB
ApoA-1
ApoB:A-1
CRP 1
Follow-up*
LDL-C
HDL-C
Non–HDL-C
Triglycerides 114.
ApoB
ApoA-1
ApoB:A-1
CRP 1
Change from
baseline
LDL-C
Mean
% change
HDL-C
Mean
% change
Non–HDL-C
Mean
% change
Triglycerides
Median (IQR) –11.
Median of %
change
ApoB
Mean
% change
ApoA-1
Mean
% change
ApoB:A-1
Mean
% change
CRP
Median (IQR) –0
Median of %
change
Values are mean  SD and
the average on-treatment
protein (CRP) measuremen
Apo ¼ apolipoprotein;
cholesterol.
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1016RESULTS
PAT I ENT CHARACTER I ST I CS . Table 1 presents
baseline demographics, clinical characteristics, and
concomitant medications in men (n ¼ 765) andFindings
Total
(N ¼ 1,039)
Women
(n ¼ 274)
Men
(n ¼ 765) p Value
120.0  28.1 123.8  30.6 118.6  27.0 0.01
45.0  11.3 49.9  12.1 43.2  10.4 <0.001
148.7  33.1 152.6  35.5 147.3  32.1 0.02
29 (94 to 180) 134 (100 to 167) 128 (92 to 182) 0.55
105.1  21.4 107.2  23.5 104.4  20.6 0.07
127.1  24.3 137.6  26.9 123.4  22.1 <0.001
0.86  0.24 0.81  0.23 0.87  0.24 <0.001
.6 (0.8 to 3.5) 1.8 (1.0 to 4.1) 1.5 (0.8 to 3.3) 0.004
65.6  22.6 66.8  24.8 65.1  21.8 0.46
49.3  11.9 54.3  11.9 47.6  11.3 <0.001
91.0  25.9 92.4  27.2 90.5  25.3 0.27
6 (89.5 to 154.3) 118.3 (92.9 to 154.7) 113.3 (87.7 to 154.3) 0.23
73.7  18.8 75.4  21.1 73.1  17.9 0.25
141.9  23.1 152.0  22.6 138.3  22.1 <0.001
0.53  0.16 0.51  0.17 0.54  0.16 0.001
.0 (0.5 to 2.2) 1.3 (0.7 to 3.2) 1.0 (0.5 to 2.0) <0.001
–54.4  30.1 –56.8  32.8 –53.5  29.1 0.12
–43.7  19.7 –44.0  20.4 –43.6  19.4 0.51
4.3  7.7 4.3  8.6 4.4  7.4 0.84
11.3  18.3 10.6  18.6 11.6  18.2 0.26
–57.8  34.0 –60.2  36.9 –56.9  32.9 0.16
–37.2  18.4 –37.5  19.0 –37.1  18.1 0.56
9 (–46.6 to 18.2) –11.6 (–41.4 to 18.0) –12.8 (–48.9 to 18.9) 0.80
–10.3 –9.2 –10.9 0.71
–31.5  20.8 –31.8  22.5 –31.4  20.2 0.77
–28.6  18.2 –27.9  22.3 –28.9  16.4 0.97
14.6  20.2 14.1  21.6 14.8  19.8 0.71
13.4  17.9 12.3  17.5 13.8  18.0 0.26
–0.32  0.19 –0.30  0.18 –0.33  0.19 0.01
–36.1  16.2 –35.4  17.1 –36.3  15.9 0.61
.4 (–1.6 to 0.2) –0.5 (–1.8 to 0.2) –0.4 (–1.5 to 0.1) 0.74
–33.3 –30.0 –33.3 0.44
median (interquartile range [IQR]). *Laboratory values obtained during treatment are
of all post-baseline values. All lipoprotein measurements are in mg/dl, and C-reactive
ts are mg/l.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoproteinwomen (n ¼ 274). Compared with men, women were
older (59.2  9.0 years of age vs. 57.1  9.0 years of
age, p < 0.001), more likely to be hypertensive (80.3%
vs. 66.8%, p < 0.001) or diabetic (21.2% vs. 13.2%,
p ¼ 0.002), and less likely to have had a prior myocar-
dial infarction (18.2% vs. 26.7%, p ¼ 0.005) or receive
concomitant aspirin (55.8% vs. 63.4%, p ¼ 0.03), beta-
blocker (55.5% vs. 62.7%, p ¼ 0.03), or nitrate therapy
(78.5% vs. 84.2%, p ¼ 0.03).
LABORATORY MEASUREMENTS. Table 2 describes
baseline, follow-up, and changes of biochemical
measurements. At baseline, compared with men,
women had higher LDL-C (123.8  31 mg/dl vs. 118.6 
27 mg/dl, p ¼ 0.01), high-density lipoprotein choles-
terol (HDL-C) (49.9  12 mg/dl vs. 43.2  10 mg/dl,
p < 0.001), apolipoprotein (Apo) A-1 (137.6  27 mg/dl
vs. 123.4  22 mg/dl, p < 0.001), and C-reactive
protein (CRP) (1.8 [IQR: 1.0 to 4.1] mg/l vs. 1.5 [IQR:
0.8 to 3.3] mg/l, p ¼ 0.004) levels, but a lower
ApoB:A-1 ratio (0.81  0.23 vs. 0.87  0.24, p < 0.001).
Following study treatment, LDL-C levels became
similar across both sexes (66.8  24 mg/dl vs. 65.1 
22 mg/dl, p ¼ 0.46), but women continued to
demonstrate higher HDL-C (54.3  12 mg/dl vs. 47.6 
11 mg/dl, p < 0.001), ApoA-1 (152.0  23 mg/dl vs.
138.3  22 mg/dl, p < 0.001), and CRP (1.3 [IQR: 0.7 to
3.2] mg/l vs. 1.0 [IQR: 0.5 to 2.0] mg/l, p < 0.001)
levels, but a lower ApoB:A-1 ratio (0.51  0.17 vs. 0.54
 0.16, p ¼ 0.001) compared with their male
counterparts.
UNIVARIATE SEX-RELATED DIFFERENCES OF BASE-
LINE AND CHANGE IN ULTRASONIC PARAMETERS.
Table 3 describes the baseline and change of IVUS
measurements. Compared with men at baseline,
women had lower plaque burden (PAV: 34.0  8% vs.
37.2  8.2%, p < 0.001; TAV: 122.4  55.2 mm3 vs.
151.9  62.8 mm3, p < 0.001) and smaller lumen (231.0
 74 mm3 vs. 254.5  93 mm3, p ¼ 0.001) and EEM
(353.4  116 mm3 vs. 406.4  140 mm3, p < 0.001)
volumes. However, women demonstrated greater
PAV regression than men (–1.52  0.18% vs. –1.07 
0.10%, p < 0.001). TAV regression did not signiﬁ-
cantly differ between women and men (–8.27  0.90
mm3 vs. –6.59  0.53 mm3, p ¼ 0.11). There were no
sex-related differences for changes in lumen (0.74 
1.8 mm3 vs. 1.04  1.1 mm3, p ¼ 0.89) or EEM (–7.01 
2.28 mm3 vs. –5.74  1.35 mm3, p ¼ 0.63) volumes.
FACTORS ASSOCIATED WITH CHANGES IN
CORONARY PLAQUE BURDEN. Given the signiﬁcant
univariate PAV regression in favor of women
compared with men, Table 4 summarizes factors
associated with sex-related differences of changes in
PAV. Compared with men, women demonstrated
TABLE 3 Univariate Sex-Related Differences of Baseline and Change of
Ultrasonic Parameters
IVUS Parameter
Total
(N ¼ 1,039)
Women
(n ¼ 274)
Men
(n ¼ 765) p Value
Percent atheroma volume
Baseline 36.3  8.3 34.0  8.0 37.2  8.2 <0.001
Change from baseline –1.19  0.09 –1.52  0.18 –1.07  0.10 0.03
p value for change from baseline <0.001 <0.001 <0.001
Total atheroma volume, mm3
Baseline 144.1  62.2 122.4  55.2 151.9  62.8 <0.001
Change from baseline –7.0  0.45 –8.27  0.90 –6.59  0.53 0.11
p value for change from baseline <0.001 <0.001 <0.001
Lumen volume, mm3
Baseline 248.3  88.6 231.0  74.0 254.5  93.0 0.001
Change from baseline 0.96  0.93 0.74  1.81 1.04  1.08 0.89
p value for change from baseline 0.30 0.68 0.34
EEM volume, mm3
Baseline 392.4  135.8 353.4  116.0 406.4  140.0 <0.001
Change from baseline –6.07  1.16 –7.01  2.28 –5.74  1.35 0.63
p value for change from baseline <0.001 0.002 <0.001
Baseline values are reported as mean  SD, and change values are reported as least-squares mean  SE
after controlling for the respective baseline value. All p values reﬂect comparisons between women and men.
EEM ¼ external elastic membrane; IVUS ¼ intravascular ultrasound.
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1017greater PAV regression if they had diabetes mellitus
(–1.91  0.36% vs. –0.77  0.27%, p ¼ 0.01), had stable
coronary disease at initial presentation (–1.52  0.21%
vs. –0.83  0.13%, p ¼ 0.01), received rosuvastatin
(–1.90  0.25% vs. –1.06  0.15%, p ¼ 0.004), and had
higher baseline LDL-C levels (–1.61  0.23% vs. –0.99
 0.14%, p ¼ 0.02) or higher baseline CRP levels
(–1.72  0.25% vs. –1.11  0.16%, p ¼ 0.04). Further
analysis revealed statistical heterogeneity with
greater regression in women treated with rosuvasta-
tin versus atorvastatin (p ¼ 0.03).
MULTIVARIATE SEX-RELATED DIFFERENCES OF
CHANGES IN PLAQUE BURDEN ACCORDING TO
TREATMENT. Based on these observations, a multi-
variable linear regression analysis sought to assess if
there was a sex-treatment interaction upon change in
atheroma volume after controlling for important
covariates. Table 5 outlines the sex-related differ-
ences of baseline and multivariable-adjusted changes
in PAV and TAV according to treatment groups.
Women consistently demonstrated lower PAV and
TAV compared with men at baseline across both
treatment groups. In the atorvastatin-treated group,
women demonstrated a similar degree of PAV
regression (–1.17  0.25% vs. –1.13  0.15%, p ¼ 0.87)
and TAV regression (–7.70  1.29 mm3 vs. –5.62 
0.74 mm3, p ¼ 0.17) compared with men. In the
rosuvastatin-treated group, however, women de-
monstrated greater PAV regression (–1.88  0.25% vs.
–0.98  0.15%, p ¼ 0.002), but not TAV regression
(–9.68  1.24 mm3 vs. –7.21  0.75 mm3, p ¼ 0.09)
compared with men. Among the covariates, baseline
PAV (p < 0.001) and female sex (p ¼ 0.002) inde-
pendently associated with plaque regression,
whereas baseline nitrate use (p ¼ 0.003) and
increasing LDL-C (p ¼ 0.04) each associated with
plaque progression. Following adjustment for these
covariates, a signiﬁcant sex-treatment interaction
persisted (p ¼ 0.036) (Figure 1), suggesting that the
treatment speciﬁcation inﬂuenced the effect of sex on
change in PAV. Following adjustment for baseline
TAV, there was no signiﬁcant sex-treatment interac-
tion (p ¼ 0.51), suggesting that the treatment speci-
ﬁcation failed to inﬂuence the effect of sex on change
in TAV.
SEX-RELATED DIFFERENCES OF PLAQUE REGRES-
SION VERSUS ON-TREATMENT LDL-C LEVELS.
Figure 2 illustrates the relationship between change
in PAV and average on-treatment LDL-C levels for
men and women. For on-treatment LDL-C levels $70
mg/dl, women had similar PAV regression rates
compared with men (–1.05  0.28% vs. –0.97  0.18%,
p ¼ 0.81), whereas for on-treatment LDL-C levels<70 mg/dl, women demonstrated signiﬁcantly greater
PAV regression than men (–1.81  0.22% vs. –1.12 
0.13%, p ¼ 0.007). Figure 3 illustrates the relationship
between change in TAV and average on-treatment
LDL-C levels for men and women. For on-treatment
LDL-C levels $70 mg/dl, women had similar TAV
regression rates compared with men (–5.26  1.43 mm3
vs. –5.55  0.89 mm3, p ¼ 0.87), whereas for on-
treatment LDL-C levels <70 mg/dl, women demon-
strated signiﬁcantly greater TAV regression than men
(–10.1  1.13 mm3 vs. –7.16  0.65 mm3, p ¼ 0.023).
DISCUSSION
Although sex-related differences of cardiovascular
outcomes exist (16), this may relate to a sex-speciﬁc
clustering of risk factors (17). Yet, differential treat-
ment patterns for cardiovascular disease in men and
women may also contribute to differences in clinical
outcome between the sexes (18–20). Statins comprise
the cornerstone of our current antiatherosclerotic
armamentarium, yielding widespread clinical bene-
ﬁts. A consistent under-representation of women in
randomized clinical trials, however, has led to the
publication of meta-analyses reporting conﬂicting
results regarding the efﬁcacy of statins in women
(21,22). This inconsistency has created confusion and
controversy among physicians, resulting in some
openly questioning the merits of prescribing statins
to women (5,23,24), despite clinical trials that
enrolled both men and women reporting beneﬁt (25).
TABLE 4 Subgroup Analysis for Between-Sex Comparisons of Changes in PAV
Clinical Characteristics
(Women, Men) Women
p Value for
Change From
Baseline (Women) Men
p Value for
Change From
Baseline (Men)
p Value for
Men Versus
Women
p Value for
Interaction
Age, yrs < median (102, 403) –1.74  0.30 <0.001 –1.18  0.15 <0.001 0.10 0.83
Age, yrs $ median (172, 362) –1.39  0.21 <0.001 –0.94  0.15 <0.001 0.08
Diabetes (58, 101) –1.91  0.36 <0.001 –0.77  0.27 0.006 0.01 0.06
No diabetes (216, 664) –1.43  0.20 <0.001 –1.11  0.11 <0.001 0.17
Hypertension (220, 511) –1.49  0.20 <0.001 –1.10  0.13 <0.001 0.11 0.56
No hypertension (54, 254) –1.69  0.38 <0.001 –0.99  0.17 <0.001 0.09
Current smoker (89, 247) –1.69  0.32 <0.001 –1.08  0.19 <0.001 0.11 0.61
Current nonsmoker (185, 518) –1.44  0.21 <0.001 –1.06  0.12 <0.001 0.13
Acute coronary syndrome (82, 279) –1.51  0.32 <0.001 –1.48  0.17 <0.001 0.94 0.15
Stable coronary syndrome (192, 486) –1.52  0.21 <0.001 –0.83  0.13 <0.001 0.01
Rosuvastatin (141, 379) –1.90  0.25 <0.001 –1.06  0.15 <0.001 0.004 0.03
Atorvastatin (133, 386) –1.12  0.25 <0.001 –1.07  0.14 <0.001 0.88
Baseline LDL-C < median (121, 385) –1.34  0.27 <0.001 –1.14  0.15 <0.001 0.53 0.24
Baseline LDL-C $ median (151, 375) –1.61  0.23 <0.001 –0.99  0.14 <0.001 0.02
Baseline HDL-C < median (89, 421) –1.72  0.31 <0.001 –1.20  0.14 <0.001 0.13 0.91
Baseline HDL-C $ median (184, 341) –1.36  0.21 <0.001 –0.92  0.15 <0.001 0.09
Baseline triglycerides < median (123, 390) –1.45  0.27 <0.001 –1.03  0.15 <0.001 0.18 0.70
Baseline triglycerides $ median (150, 372) –1.55  0.23 <0.001 –1.10  0.15 <0.001 0.10
Baseline CRP < median (117, 365) –1.36  0.26 <0.001 –1.08  0.14 <0.001 0.36 0.40
Baseline CRP $ median (148, 362) –1.72  0.25 <0.001 –1.11  0.16 <0.001 0.04
Baseline PAV < median (165, 354) –0.82  0.20 <0.001 –0.44  0.14 0.002 0.12 0.49
Baseline PAV $ median (109, 411) –2.24  0.30 <0.001 –1.70  0.15 <0.001 0.11
Values are least-squares mean  SE. Coronary syndrome was designated as the mode of presentation for the initial coronary angiogram during the time in which baseline
intravascular ultrasound (IVUS) and study enrollment occurred.
PAV ¼ percent atheroma volume; other abbreviations as in Table 2.
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1018This analysis reports the novel ﬁnding of sex-
related differences of the serial response of coronary
atheroma following 2 years of maximally intensive
statin therapy. Female sex was independently asso-
ciated with coronary atheroma regression to this
treatment, and more likely occurred in womenTABLE 5 Multivariable-Adjusted Sex-Related Differences Between Ba
IVUS Parameter
Atorvastatin
Women
(n ¼ 133)
Men
(n ¼ 386)
Percent atheroma volume
Baseline 33.3  8.2 36.9  8.2
Adjusted change from baseline‡ –1.17  0.25 –1.13  0.15
p value for change from baseline <0.001 <0.001
Total atheroma volume, mm3
Baseline 117.6  56.5 153.2  63.6
Adjusted change from baseline§ –7.70  1.29 –5.62  0.74
p value for change from baseline <0.001 <0.001
Values are mean  SD for baseline values and least-squares mean  SE for change valu
group. †Reﬂects comparisons between men and women within the rosuvastatin-treated
for baseline PAV, sex, baseline nitrate use, and change in LDL-C). Interaction p value for s
TAV (controlling for baseline TAV, sex, change in LDL-C, baseline non–HDL-C, age, baselin
treatment ¼ 0.51.
TAV ¼ total atheroma volume; other abbreviations as in Tables 1, 2, 3 and 4.with diabetes mellitus, stable angina pectoris, and
higher baseline LDL-C and CRP levels. A signiﬁcant
interaction emerged between sex and treatment
speciﬁcation, with rosuvastatin-treated women de-
monstrating the greatest degree of plaque regression
compared with all other treatment groups. Bothseline and Changes in Plaque Volume According to Treatment
Rosuvastatin
p Value*
Women
(n ¼ 141)
Men
(n ¼ 379) p Value†
<0.001 34.7  7.7 37.4  8.2 0.001
0.87 –1.88  0.25 –0.98  0.15 0.002
<0.001 <0.001
<0.001 127.0  53.7 150.4  62.1 <0.001
0.17 –9.68  1.24 –7.21  0.75 0.09
<0.001 <0.001
es. *Reﬂects comparisons between men and women within the atorvastatin-treated
group. ‡Multivariable adjustment for factors inﬂuencing change in PAV (controlling
ex by treatment ¼ 0.036. §Multivariable adjustment for factors inﬂuencing change in
e beta-blocker use, and concomitant ACE inhibitor use). Interaction p value for sex by
FIGURE 1 Interaction Between Sex and Treatment Upon Change in PAV
The interaction between sex and treatment speciﬁcation upon change in
coronary atheroma volume. PAV ¼ percent atheroma volume.
FIGURE 2 Sex-Related Variations of Changes in PAV Versus Average
On-Treatment LDL-C Levels
Locally weighted (moving average) plot outlining the relationship between
predicted changes in percent atheroma volume (PAV) from baseline versus
average on-treatment low-density lipoprotein cholesterol (LDL-C) levels
stratiﬁed according to sex. The average on-treatment LDL-C values on the x-
axis reﬂect the ﬁrst to 99th percentile LDL-C values in the SATURN (Study of
Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin
Versus Atorvastatin) study; blue represents men, pink represents women. The
dotted green line represents an on-treatment LDL-C value of 70 mg/dl. For
on-treatment LDL-C <70 mg/dl, the least-squares mean (LSM) changes in
PAV for women versus men are –1.81  0.22% versus –1.12  0.13%
(p ¼ 0.007). For on-treatment LDL-C$70 mg/dl, the LSM changes in PAV for
women versus men are –1.05  0.28% versus –0.97  0.18% (p ¼ 0.81).
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1019sexes demonstrated similar plaque regression rates
when on-treatment LDL-C values were $70 mg/dl.
For on-treatment LDL-C levels <70 mg/dl, however,
women demonstrated signiﬁcantly greater coronary
atheroma regression than their male counterparts.
Although the biological mechanisms underlying this
observation need further exploration, these ﬁndings
highlight the efﬁcacy of high-intensity statins in
women with coronary artery disease, supporting the
latest guideline recommendations of potent statin
therapy in individuals with proven atherosclerotic
cardiovascular disease. These data also provide novel
insights into possible inﬂuences of sex on the natural
history of coronary atherosclerosis and subsequent
cardiovascular risk.
Vascular imaging, particularly serial coronary
IVUS, has proven pivotal in deﬁning factors promot-
ing the progression, and regression, of athero-
sclerosis. In serial studies of coronary atheroma
volume, the baseline extent of disease has consis-
tently and independently predicted plaque regression
to disease-modifying therapies, such that those with
greater baseline plaque burden invariably demon-
strate more disease regression (15), particularly in
response to high-intensity statins (26). In the SATURN
study, despite harboring less baseline coronary
atheroma volume than their male counterparts,
women still demonstrated greater atheroma regres-
sion than men, a ﬁnding that reinforces the signiﬁ-
cance of this observation in the present analysis. A
prior pooled analysis of 978 patients from 3 trials
employing serial coronary IVUS assessment of plaque
progression showed that despite a greater cardiovas-
cular risk-factor proﬁle, women displayed less base-
line plaque burden than men (27). Following a variety
of risk-modifying therapies, the serial plaque
response of women mirrored that of men. Meta-
analyses, however, are subject to the possibility of
confounding by inclusion of studies with differing
treatments and entry criteria. These analyses imply
that although women typically present with a lower
disease burden than men, their disease appears more
susceptible to the antiatherosclerotic effects of
disease-modifying therapies.
Other advanced imaging techniques have eluci-
dated sex-speciﬁc differences in plaque character
and composition. High-resolution cardiac magnetic
resonance of carotid plaques found intraplaque
hemorrhage and lipid core to more frequently occur
in men than in women (28). A post-hoc analysis from
the PROSPECT (Providing Regional Observations
to Study Predictors of The Events in the Coronary
Tree) study (29) found sex-related differences of
nonculprit vessel coronary plaque composition in
FIGURE 3 Sex-Related Variations of Changes in TAV Versus Average
On-Treatment LDL-C Levels
Locally weighted (moving average) plot outlining the relationship between
predicted changes in total atheroma volume (TAV) from baseline versus
average on-treatment LDL-C levels stratiﬁed according to sex. The average
on-treatment LDL-C values on the x-axis reﬂect the ﬁrst to 99th percentile
LDL-C values in the SATURN (Study of Coronary Atheroma by Intravascular
Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) study; blue repre-
sents men, pink represents women. The dotted green line represents an on-
treatment LDL-C value of 70 mg/dl. For on-treatment LDL-C <70 mg/dl, the
least squares mean (LSM) changes in TAV for women versus men are –10.1 
1.13 mm3 vs. –7.16  0.65 mm3 (p ¼ 0.023). For on-treatment LDL-C $ 70
mg/dl, the LSM changes in PAV for women versus men are –5.26  1.43 mm3
versus –5.55  0.89 mm3 (p ¼ 0.87).
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1020individuals less than, but not greater than, 65 years
of age (30). Women younger than 65 years had less
ﬁbroatheromas, considered a more advanced form of
atheroma, than similarly-aged men. In parallel to
this, a pre-speciﬁed post-hoc serial plaque composi-
tion analysis of the SATURN study revealed signiﬁ-
cant reductions in the number of lipid-rich
pathological intimal thickening lesions, yet static
numbers of ﬁbroatheromas, following high-intensity
statin therapy (31). Collectively, this may explain
why women in the SATURN study, with a mean age
of 59.2  8.5 years, demonstrated a greater beneﬁt
than men in terms of plaque regression. Younger
women may simply possess a more modiﬁable (lipid-
rich) atheromatous substrate than similarly-aged
men and thus, derive a greater antiatherosclerotic
beneﬁt from aggressive statin-mediated LDL-C
lowering.
The most recent treatment guidelines now recom-
mend high-intensity statin therapy in all individuals
with proven atherosclerotic cardiovascular disease
(4), and do not advocate a speciﬁc LDL-C target
following commencement of this therapy. However,the present analysis demonstrates the novel ﬁnding
of an incremental antiatherosclerotic beneﬁt in
women compared with men, when achieving on-
treatment LDL-C levels <70 mg/dl; a cutoff level
endorsed by previous treatment guidelines (32). A
post-hoc analysis of the PROVE IT-TIMI 22 (Pravas-
tatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis In Myocardial Infarction 22)
trial revealed that women achieved less
LDL-C reduction than men following high-intensity
statin therapy, yet derived equal clinical beneﬁt.
This suggests superior risk-reduction in women
compared with men per unit of LDL-C lowered (33),
which appears consistent with the ﬁndings of the
present analysis. However, these collective post-hoc
ﬁndings will ultimately need testing in a prospec-
tive randomized controlled trial. Therefore, at pre-
sent, it remains unclear if women derive greater
clinical beneﬁt than men with further LDL-C
lowering. Furthermore, the SATURN study was not
powered to detect differences in clinical outcomes.
A prior pooled analysis of over 4,100 patients from
6 clinical trials, inclusive of nearly 1,300 women,
however, demonstrated a signiﬁcant association
between the rate of coronary atheroma progression
and incident clinical events, driven chieﬂy by rates
of repeat coronary revascularization procedures (15).
A recent pooled analysis of serial left main coronary
atheroma progression demonstrated a similar asso-
ciation (34).
This analysis of the SATURN study found a signif-
icant sex-treatment interaction, suggesting a greater
antiatherosclerotic effect in women treated with
rosuvastatin. The reasons for this ﬁnding are unclear,
and warrant further investigation. Nevertheless,
one may speculate on the mechanistic basis of these
observations. Various statins may exert different
biological effects upon the vessel wall, further inﬂu-
enced by a sex-speciﬁc milieu. The more signiﬁcant
regression of PAV compared with TAV found in
women (compared with men) may simply reﬂect a
more potent effect of rosuvastatin upon the arterial
wall. This ﬁnding may also be a reﬂection of the
magnitude of achieved LDL-C levels. Indeed,
Figures 2 and 3 highlight signiﬁcantly greater PAV and
TAV regression in women compared with men
when achieved LDL-C levels are <70 mg/dl. Lipido-
mic proﬁling has uncovered differential effects of
atorvastatin and rosuvastatin on the detailed plasma
lipoprotein subcompartments (35). Further pharma-
cogenomic- and metabolomic-based analyses may
uncover sex-speciﬁc differences of various statins on
the arterial wall, particularly regarding the delipida-
tion of atherosclerotic plaque.
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1021STUDY LIMITATIONS. This analysis has some limita-
tions. Common to the limitations of many contem-
porary, large-scale randomized controlled trials, the
SATURN study enrolled relatively fewer women than
men, comprising 26% of the study population. In
addition, the post-hoc ﬁndings of signiﬁcantly greater
plaque regression in rosuvastatin-treated women
compared with men and in women with LDL-C <70
mg/dl requires replication in a larger cohort of
women evaluated prospectively and should there-
fore be considered as hypothesis generating. How-
ever, the SATURN study comprises the largest
cohort of women who have undergone serial coro-
nary IVUS evaluation in a single trial, with the
longest duration of follow-up compared with
previous coronary imaging trials. These features
provided enough statistical power to explore sex-
related differences of serial plaque responses
following maximally intensive statin therapy. The
present analysis does not apply directly to a pri-
mary prevention setting. IVUS is invasive, and is
thus inappropriate for evaluating asymptomatic,
low-risk individuals. The present analysis did not
evaluate plaque composition. Baseline differences
in coronary plaque composition, and their potential
inﬂuence on serial responses, may have provided
additional mechanistic insight into the observed
sex-speciﬁc differences of serial plaque behavior
following high-intensity statin treatment. Data re-
garding menopausal status and use of hormone
replacement therapy were not collected in the
SATURN study. This data may have also provided
additive mechanistic insight into the observedsex-speciﬁc differences in serial plaque responses
to potent statin therapy.
CONCLUSIONS
Long-term maximally intensive statin therapy re-
sulted in women experiencing greater coronary
atheroma regression than men, particularly below on-
treatment LDL-C levels of 70 mg/dl, and especially in
rosuvastatin-treated women. Female sex indepen-
dently associated with plaque regression to high-
intensity statins. The ﬁnding of a sex-treatment
interaction in the degree of plaque regression should
provide impetus for future research to probe mecha-
nisms accounting for sex-speciﬁc variations of
atheroma progression. These data support the use of
high-intensity statin therapy in women with athero-
sclerotic cardiovascular disease, afﬁrming recent
treatment guidelines endorsing the use of potent
statin therapy. In addition, dedicated clinical trials
involving women may foster the development of
personalized medicine.
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